Abstract | Neuronal inclusions comprised of the microtubule-associated protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's disease -the most prevalent tauopathy -misfolded tau is probably a key pathological agent. The recent failure of amyloid-β-targeted therapeutics in Phase III clinical trials suggests that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer's disease. Here, we focus on strategies directed at reducing misfolded tau and compensating for the loss of normal tau function. 
. Because of this shared pathological feature, these various neurodegenerative diseases have been called 'tauopathies' , although there are clear distinctions in the phenotypic manifestations of these disorders.
The insoluble tau deposits that are found in the brains of patients with tauopathies are comprised of fibrils and are typically found within the cell bodies and dendrites of neurons 3 , where they are referred to as neurofibrillary tangles (NFTs) and neuropil threads (FIG. 1) . The occurrence of fibrillar tau inclusions in tauopathies suggests that they have a key role in the observed clinical symptoms and pathology. This hypothesis is supported by the correlation of NFT density with cognitive decline in Alzheimer's disease [4] [5] [6] . However, no tau mutations have been identified in Alzheimer's disease, whereas the inherited early-onset forms of the disease can result from mutations in the amyloid precursor protein (APP) or presenilins that lead to increased synthesis of the amyloid-β (Aβ) peptide found in the hallmark plaques of Alzheimer's disease brain 7, 8 . These genetic data led to an Aβ-centric view of Alzheimer's disease which, although still prevalent, was tempered by the later discovery that FTLD with Parkinsonism linked to chromosome 17 (FTLD17) resulted from mutations in the gene encoding tau 9, 10 . Because patients with FTLD17 have Alzheimer's disease-like tau deposits in their brains 11 , it seems reasonable to surmise that this common tau pathology causes disease in Alzheimer's disease and other tauopathies, albeit in the absence of tau gene mutations. In the case of Alzheimer's disease, there is therefore compelling evidence to suggest that both Aβ and tau are diseasecausing agents. Although the link between these two molecules in Alzheimer's disease is not fully understood, the prevailing viewpoint is that misfolded Aβ species initiate cellular events that result in tau aggregation 12 . Tau stabilizes microtubules within cells 13, 14 and is particularly abundant in neurons 15 , in which microtubules serve as the 'tracks' upon which cellular cargo is transported in axons (FIG. 2) . Humans express six tau isoforms that result from alternative splicing of exons 2, 3 and 10 of the tau gene 16, 17 , and the absence or presence of exon 10 leads to tau species that contain either three (3R) or four (4R) carboxyl-terminal microtubule-binding repeats (FIG. 3) . Unsurprisingly, 4R tau isoforms bind microtubules with greater avidity than 3R isoforms 18 , and there is approximately equimolar 4R and 3R tau in normal individuals. Interestingly, a substantial proportion of the known tau mutations in FTLD17 affect exon 10 splicing (FIG. 3) , which leads to an increase in the 4R/3R ratio 2, 9, 10 and suggests that over-stabilization of microtubules results in disease. An alternative explanation is that 4R tau more readily forms aggregates that contribute to disease 19 . The remaining tau mutations that cause FTLD17 are missense mutations within the coding region of the tau gene 2,9,10 (FIG. 3) . Studies show that some of these amino-acid changes decrease the ability of tau to bind microtubules [20] [21] [22] and/or increase the propensity of tau to form insoluble fibrils in vitro [23] [24] [25] .
The causes of tau aggregation in sporadic tauopathies are not fully understood. one post-translational modification that seems to alter the properties of tau in ways that resemble FTLD17 mutations is hyperphosphorylation, which occurs in all tauopathies 26, 27 . Tau is normally phosphorylated at multiple serine and threonine residues 28 , and hyperphosphorylation (FIG. 3) reduces microtubule binding [29] [30] [31] [32] and may enhance aggregation 31, 33, 34 . Therefore, it is possible that changes in protein kinase and/or phosphatase activities could enhance tau phosphorylation with consequent loss-of-function (LoF) and/or gain-of-function (GoF) toxicities. Additional post-translational modifications may also contribute to tau dysfunction. For example, tau undergoes a specific type of serine-threonine O-glycosylation, and these modifications can reduce the extent of tau phosphorylation 35, 36 . A decrease in tau O-glycosylation could therefore result in increased hyperphosphorylation. Tau can also be tyrosine phosphorylated 37 , sumoylated and nitrated 38 , although the effects of these modifications on tau are not fully understood. Another post-translational event that may facilitate tau aggregation is proteolytic cleavage, as it seems that both calpain 39 and caspases 40 can act on tau to produce fragments that may have an increased propensity to aggregate. Finally, it is known that tau fibrillization in vitro requires the presence of anionic cofactors such as heparin, RNA or negatively charged lipids 41, 42 , and it is possible that changes in the intracellular content of these molecules may facilitate tau deposition in tauopathies.
The knowledge gained from studying the mutations that cause FTLD17 and an increased understanding of how the post-translational modifications of tau affect its function has led to a growing interest in developing therapeutics that target pathological tau. Most tau-directed drug discovery programmes are in early research stages and are considerably less advanced than Aβ-focused programmes. However, recent notable failures in pivotal clinical trials with agents such as tramiprosate 43 and flurbiprofen 44 , which were aimed at reducing the Aβ burden in the brains of patients with Alzheimer's disease, underline the need to pursue other therapeutic approaches, including those that reduce the levels of pathological tau. It is thus timely to review recent advancements in taubased drug discovery efforts and the relative merits of these strategies.
Compensating for tau LOF evidence that tau mutations and hyperphosphorylation can affect microtubule binding suggests that impairment of microtubule function and axonal transport contributes to neurodegeneration in Alzheimer's disease and related tauopathies (FIG. 2) . A reduction of the stabilized microtubule marker, acetyl-tubulin, has been observed in NFT-containing neurons in the brains of patients with Alzheimer's disease 45 and after tau deposition in a rat hippocampal slice model 46 . Importantly, a reduction in microtubule density and fast axonal transport (FAT) has been observed in a transgenic mouse model that develops hyperphosphorylated tau inclusions in neurons of the Alzheimer's disease or related tauopathies show abundant neurofibrillary tangles (NFTs) and neuropil threads that are comprised of pathological tau (also known as MAPT). These tau deposits can be visualized by treating brain slices with certain silver stains or by immunostaining with antibodies that recognize tau, as shown. Darkly stained NFTs and dense tau neuropil threads that yield a nearly uniform brown staining in a hippocampal section of an Alzheimer's disease brain can be seen. b | A schematic representation of NFTs and neuropil threads, with an example of tau fibrils that resemble those found in NFTs (inset). cortex, brainstem and spinal cord 47 . Finally, in patients with Alzheimer's disease, a reduced microtubule density was observed in pyramidal neurons compared with age-matched controls, although the change seemed to be unrelated to the presence of NFTs 48 . There are data that contradict the viewpoint that tau LoF contributes to neurodegeneration. For example, FAT was not affected in tau-knockout mice 49 , and human APPtransgenic mice that were crossed with tau-deficient mice showed improved cognitive performance compared with APP-transgenic mice expressing normal amounts of tau 50 . However, constitutive gene knockout can lead to compensatory changes during development, and it has been reported that tau-knockout mice have increased expression of the microtubule -associated protein 1a (MAP1a) 51 . Moreover, tau-knockout mice are not normal: they develop cognitive as well as motor deficits with age, and primary hippocampal neurons from these animals show delayed axonal extension 52, 53 . Inducible tau-knockout mice have not yet been evaluated; these animals may provide a more accurate measure of the importance of tau.
The hypothesis that tau LoF contributes to neuronal dysfunction has been further tested by treating tautransgenic mice that display microtubule and motor deficits with the micotubule-stabilizing drug paclitaxel 47, 54 (FIG. 4) . After 3 months of drug treatment, the mice showed a significant improvement of FAT and microtubule density compared with vehicle-treated mice. Furthermore, there was a marked improvement in motor function in the paclitaxel-treated mice. Because paclitaxel does not readily cross the blood-brain barrier (BBB), the observed drug-induced changes presumably resulted from paclitaxel uptake at peripheral neuromuscular junctions and subsequent retrograde transport to spinal motor neurons. These results show that small-molecule drugs can compensate for tau LoF. Microtubule-stabilizing agents that readily cross the BBB might lead to similar improvements in tauopathy brains. Recently, the octapeptide containing the amino-acid sequence NAPvSIPQ (known as NAP) which crosses the BBB, was found to promote microtubule assembly 55 . Intranasal NAP administration for 9 months to 9-month-old transgenic mice that develop Aβ and tau deposits resulted in a reduction in tau phosphory lation and Aβ levels 56 . Furthermore, in older transgenic mice that had developed moderate pathology, NAP treatment reduced tau phosphorylation, although Aβ levels were unaffected 57 . The mechanism whereby NAP alters tau phosphorylation and Aβ levels in young transgenic mice is unclear, as it is not evident that stabilization of microtubules would lead to these changes. Nonetheless, these data are intriguing and support the concept that drug-induced stabilization of microtubules could be beneficial in tauopathies.
A challenge when attempting to treat Alzheimer's disease and related tauopathies with microtubule-stabilizing compounds is identifying molecules that readily reach the brain. Although intranasal administration of NAP seemed to result in effective brain levels of this molecule, many of the more traditional microtubule-stabilizing agents, including the taxanes, have poor BBB penetration 58 . This is due, at least in part, to many of the taxanes being substrates of the P-glycoprotein transporter that actively pumps xenobiotics from the cells that line the BBB back into the blood 59 . Identifying microtubule-stabilizing compounds with good brain penetration is important not only because this is the site of pathology in human tauopathies, but also because it will be possible to achieve efficacious brain concentrations at lower plasma drug levels than for drugs that have low BBB penetration. Keeping peripheral levels of microtubule-stabilizing drugs as low as possible is important as these compounds are potent antimitotic agents that can have adverse side effects. Based on the absence of observable morbidities in the tau-transgenic mice that showed motor improvements upon paclitaxel treatment 54 , there is hope that low brain concentrations of microtubule-stabilizing drugs will be required to stabilize neuronal microtubules in tauopathies. Further analysis of microtubule-stabilizing compounds to identify those that can gain access to the brain, followed by testing in animal models of tauopathy, will provide further information on the efficacy and safety of this approach.
Inhibition of tau hyperphosphorylation
Challenges associated with reducing tau phosphorylation. Normal tau is phosphorylated on several residues and the extent of this phosphorylation is considerably increased in the brains of patients with Alzheimer's disease 60, 61 . Although ~40 serine-threonine tau phosphorylation Microtubules serve as 'tracks' that are essential for normal trafficking of cellular cargo along the lengthy axonal projections of neurons. b | It is thought that tau function is compromised in Alzheimer's disease and other tauopathies. This probably results from both tau hyperphosphorylation, which reduces the binding of tau to microtubules, and the sequestration of hyperphosphorylated tau into neurofibrillary tangles (NFTs), which reduces the amount of tau that is available to bind microtubules. The loss of tau function leads to microtubule instability and reduced axonal transport, which could contribute to neuropathology. Alternative splicing and translation
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Pseudophosphorylation
The substitution of phosphorylated serine and threonine residues in a protein with aspartic acid or glutamic acid residues which, like phosphorylated serine and threonine, carry a negative charge at physiological pH. The effect on the protein is therefore similar to phosphorylation of serine and threonine residues.
sites have been described 62 , only a small number of hyperphosphorylation sites are well characterized (FIG. 3) ; most of them flank the microtubule-binding domains, although ser262 and ser356 reside within these regions. Phosphorylation at ser262, thr231 and ser235 was found to reduce tau binding to microtubules 63 , and phosphory lation or pseudophosphorylation of a number of sites has been shown to enhance tau fibrillization 31, 33, 64 . conversely, phosphorylation at ser214 and ser262 may prevent tau aggregation 65 . Because hyperphosphory lation could lead to tau LoF or GoF, identifying inhibitors of the appropriate kinases has considerable therapeutic appeal.
Kinase inhibitors are being actively pursued in the pharmaceutical industry for numerous clinical applications, particularly for the treatment of cancers. Nonetheless, there are considerable challenges to the development of tau kinase inhibitors. Because current kinase inhibitors are generally directed to the common ATP-binding site that is shared by all members of this family, achieving kinase selectivity has proved difficult 66 .
Furthermore, inhibiting tau hyperphosphorylation requires an understanding of the specific enzymes that are involved in these modifications. Several kinases have been shown to be capable of phosphorylating tau in vitro, including proline-directed kinases such as mitogen-activated protein kinase 1 (MAPK1; also known as eRK2), glycogen synthase kinase 3 (GSK3) and cyclindependent kinase 5 (cDK5), as well as non-prolinedirected enzymes such as casein kinase 1, protein kinase A, and MAP/microtubule affinity-regulating kinase 1 (MARK1) 62, 67, 68 . However, uncertainty remains about which of these is most important for tau hyperphosphorylation in human disease.
There is substantial evidence to suggest that cDK5 and GSK3 are relevant kinases in tauopathies. GSK3 exists in two homologous α-and β-isoforms but, because the reagents used in many studies do not differentiate between these two species, their relative contributions to pathology are unclear. GSK3 colocalizes with NFTs 69 , although its activity does not seem to be upregulated in the Alzheimer's disease brain 70 . overexpression of GSK3β in transgenic mice has been reported to increase tau hyperphosphorylation and to cause behavioural deficits 71, 72 . cDK5 activity 73 and the levels of cDK5 activator 1 (cDK5R1, which is cleaved into p25 and p35) 74 have been reported to be upregulated in the brains of patients with Alzheimer's disease. Like GSK3, cDK5 has also been shown to be associated with nascent NFTs [75] [76] [77] . In addition, co-expression of p25 and mutant human tau in mice led to the formation of NFTs with resulting neurodegeneration 78 . Interestingly, both cDK5 (ReF. 79) and GSK3 have been implicated in the upregulation of Aβ synthesis, with inhibition of GSK3α and GSK3β reported to decrease Aβ levels [80] [81] [82] . Also, there seems to be a link between cDK5 and GSK3β activity, as inhibition of cDK5 in mice overexpressing p25 led to an increase of tau phosphorylation by GSK3β 83 . This implies that inhibition of cDK5 may not lead to a desired reduction of tau hyperphosphorylation. Among the candidate non-proline-directed tau kinases, MARK1 could be the most promising candidate to reduce tau hyperphosphorylation. MARK1 phosphorylates several microtubule-associated proteins in addition to tau, and cells that overexpress this kinase show increased tau phosphorylation 84 . MARK1 is localized to tau fibrils in the Alzheimer's disease brain 85 , and overexpression of the MARK1 orthologue MARK2 (also known as PAR1 homologue) in flies co-expressing human tau resulted in increased tau phosphorylation and enhanced neurotoxicity 86 . A further challenge in developing tau kinase inhibitors, in addition to those mentioned above, is the possibility of target-related side effects, as most kinases regulate several cellular processes. GSK3 is perhaps best known for its involvement in glycogen metabolism and as a drug target for metabolic disease 87 . cDK5 is essential for survival in mice and has a key role in neuronal development 88 . Similarly, MARK1 is involved in axonal transport and neurite growth 89, 90 . Although kinase inhibitors have been used successfully in oncology, it remains to be determined whether these molecules can A small number of tau kinase inhibitors (FIG. 4) have progressed to efficacy testing in tau-based animal models
. These data are briefly discussed here as they provide important information about the merits of this approach. The development of several transgenic mouse lines that overexpress tau with FTLD17-associated mutations 92 has provided important research tools for compound evaluation. These mice typically show an age-dependent formation of intraneuronal hyperphosphorylated tau inclusions that mimic many aspects of the NFTs observed in human tauopathies, including neuritic pathology and axonal degeneration.
Analysis of tau phosphorylation inhibitors in animal models. Most in vivo efficacy studies of tau kinase inhibitors have examined the effects of GSK3 inhibition. Administration of the GSK3 inhibitor Licl for ~1 month to transgenic mice that overexpress mutant human tau resulted in a reduction in tau phosphorylation and the levels of insoluble tau 93, 94 . Licl has effects on enzymes other than GSK3, but it has been shown that treatment with the reasonably specific GSK3 inhibitor AR-A014418 (FIG. 4) leads to a reduction of insoluble tau in these transgenic mice that is comparable to that observed with Licl. A 4-month Licl treatment of young transgenic mice that express the shortest human tau isoform led to a reduction of tau pathology and a behavioural improvement 95 . Interestingly, although tau phosphorylation was decreased during the initial month of dosing in these mice, this effect was not seen by the end of the dosing regimen 95 . The attenuated tau pathology in the Licltreated mice may therefore have resulted from the transient inhibition of GSK3 and/or from the increase in tau ubiquitylation that was observed in these animals. More recently, Licl was administered to transgenic mice that overexpress both mutant human tau and GSK3β, and which develop age-dependent tau hyperphosphorylation accompanied by NFT formation. Treatment of presymptomatic animals with Licl for 7.5 months prevented tau hyperphosphorylation and the onset of tau pathology, whereas administration of Licl to mice with existing tau pathology resulted in a reduction of tau phosphorylation, although NFTs persisted 96 . A comparable effect was observed when tetracycline-controlled GSK3β expression was downregulated in these older mice, suggesting that the effects of Licl were specifically due to inhibition of GSK3β 96 . Finally, Licl has been administered to 15-month-old transgenic mice that develop Aβ plaques and tau fibrils in their brain 97 . Daily Licl treatment for 1 month led to reduced tau phosphorylation without affecting the Aβ plaque burden. However, the drug treatment did not rescue memory deficits in these animals. Although studies of Licl in patients with Alzheimer's disease are sparse, a recent 10-week clinical trial of Licl in 71 patients with mild Alzheimer's disease did not show clinical or biomarker efficacy 98 . whereas many in vivo studies of tau kinase inhibition have used Licl, a few additional small-molecule kinase inhibitors have been evaluated for efficacy. The nonspecific kinase inhibitor SRN-003-556 (FIG. 4) , which inhibits cDK5, GSK3 and MAPK1, was evaluated in mice that overexpress mutant human tau 99 . The compound was shown to significantly delay the development of motor deficits and decrease the amount of soluble hyperphosphorylated tau after 9 weeks of dosing. However, no reduction in NFTs was observed, suggesting that the negative effects of tau may have resulted from diffusible multimers. More recently, numerous GSK3 inhibitors were investigated in 12-day-old rats that have increased tau phosphorylation compared with adult animals 100 . Both Licl and cHIR-98014 were found to reduce tau phosphorylation in the cortex and hippocampus, whereas alsterpaullone and SB216763 (FIG. 4) were only effective in the hippocampus. 
Cross-β-fibril
A fibril composed of repeating units enriched in β-sheets that align parallel to the fibril axis with their β-strands perpendicular to this axis.
Another potential approach to modifying tau phosphorylation is through manipulation of tau O-linked glycosylation 101 . certain serine and threonine residues of tau are post-translationally modified through the addition of β-N-acetylglucosamine (O-GlcNAc), and the levels of tau phosphorylation and O-GlcNAc are reciprocally regulated such that increased levels of tau O-GlcNAc results in decreased phosphorylation 35, 36 . The cleavage of O-GlcNAc from tau is mediated by the enzyme O-GlcNAcase, and a recent study has shown that acute administration of an inhibitor of this enzyme, thiamet-G (FIG. 4) , to normal rats caused an apparent reduction of tau phosphorylation at ser396, thr231 and ser404 (ReF. 102) . So, it may be possible to modulate tau phosphorylation through inhibition of O-GlcNAcase, although it should be noted that the single in vivo study with thiamet-G was conducted in normal rats that do not have hyperphosphorylated tau. As many intracellular proteins undergo modification by O-GlcNAc, the potential side effects of chronic inhibition of this enzyme will have to be carefully examined.
Inhibition of tau oligomer and fibril assembly
As discussed above, the conversion of soluble tau into oligomeric and fibrillar species could result in tau GoF and LoF toxicities. Inhibiting tau assembly into multimeric structures might therefore prevent the formation of toxic species and increase the levels of monomeric tau, which could contribute to microtubule stabilization. Although blocking protein-protein binding with small-molecule drugs is generally thought to be difficult owing to the large surface areas that are involved in such interactions, there is growing evidence that tau multimerization can be disrupted with low-molecularmass compounds (FIG. 5) . These studies have been greatly facilitated by the discovery that tau can be induced to form well defined fibrils in vitro in the presence of certain anionic cofactors, such as heparin or negatively charged lipids 42, 103 . Moreover, the formation of these tau fibrils can be readily monitored with fluorescent dyes that recognize the cross-β-fibril structure that is common to all amyloid fibrils
. Although the tau fibrils formed in vitro are similar to the paired helical filaments (PHFs) that are seen in the brains of patients with Alzheimer's disease, other tauopathies such as progressive supranuclear palsy are characterized by straight tau filaments 2 . It therefore remains to be determined whether a compound that blocks tau fibrillization in vitro will affect all types of tau fibrils.
The first compound that was reported to inhibit tautau interactions was the dye methylene blue (FIG. 5) , which was also shown to alter the structure of existing PHFs that were isolated from the brains of patients with Alzheimer's disease 104 . This molecule is now in clinical testing for Alzheimer's disease, and Phase II data presented at the 2008 International conference on Alzheimer's Disease suggested that this compound had a positive therapeutic effect 105 , although larger Phase III studies are required to prove efficacy. Another dye-like molecule, N744, has also been identified as an inhibitor of full-length tau fibrillization and, like methylene blue, this compound could disaggregate existing filaments 106 . However, at higher concentrations N744 forms aggregates that were found to increase tau assembly 107 . A number of laboratories have screened compound libraries (BOX 2) with the goal of identifying inhibitors of tau fibrillization ( see FIG. 5 for examples). For example, the Mandelkow laboratory completed a high-throughput screen (HTS) of ~200,000 compounds in an assay in which fibrillization of a 3R tau fragment was evaluated by thioflavine S fluorescence 108 . This led to the identification of a number of anthraquinone inhibitors of tau fibril formation, including daunorubicin and adriamycin. These compounds also caused disaggregation of preformed tau fibrils if concentrations were increased above those required to prevent fibrillization, indicating that it is possible to find compounds that can both block the formation of tau fibrils and dissolve existing aggregates. Furthermore, it was shown that an anthraquinone analogue could reduce the formation of tau inclusions in N2a neuroblastoma cells that overexpress a 4R human tau fragment. A number of N-phenylamine tau fibrillization inhibitors identified from this screen were later shown to also be active in the N2a cell model 109 . This group subsequently developed a pharmacophore model from the active compounds identified in the HTS 110 , resulting in the identification of a phenylthiazolylhydrazide series of compounds that prevented tau fibrillization and aggregation in the N2a cellular model 111 . Finally, a rhodanine series of tau fibril inhibitors that disaggregated preformed tau fibrils and prevented tau aggregate formation in N2a cells was also identified 112 by this team.
other inhibitors of tau fibril assembly, identified through screening, include pheno thiazines, porphyrins and polyphenols, as determined by thioflavine T fluorescence and electron microscopic analysis of reaction products 113 . Another screen of ~51,000 compounds to identify inhibitors of heparin-induced fibrillization of a human 4R tau fragment 114 identified several active compounds, including previously described anthraquinones, phenothiazines, porphyrins and sulphonated dyes.
Box 1 | Transgenic mouse models of tauopathy
The assessment of compounds that are directed to potential tauopathy drug targets has been greatly facilitated by the development of transgenic mice that develop tau (also known as MAPT) neuropathology as they age (reviewed in ReFs 1,92). In general, mice that have been genetically altered to overexpress human tau containing one or more mutations found in patients with frontotemporal lobar degeneration with Parkinsonism linked to chromosome 17 (FTLD17) develop central nervous system inclusions comprised of hyperphosphorylated human tau. These intraneuronal aggregates resemble those observed in tauopathies, and many tau-transgenic mice also show profound neuron loss. The regional expression profile of tau in these transgenic mice depends on the promoter that is used to drive tau expression: certain transgenic lines show neuropathology that is largely restricted to the forebrain, whereas other lines have more broadly disseminated tau expression and pathology. Recently, transgenic mice have been developed in which mutated human tau expression can be regulated through the use of a repressible promoter 136 , thereby facilitating studies examining the effects of temporal tau expression. 
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Macroautophagy
A process whereby a double-membrane structure encapsulates cytosolic material and fuses with lysosomes, resulting in degradation of the sequestered matter.
In addition, novel benzofuran, pyrimidotriazine and quinoxaline inhibitors were discovered. Secondary analyses revealed that many of the compounds were inactive when dithiothreitol (DTT) was omitted from the tau assembly reaction, possibly because these compounds form peroxides in the presence of DTT that alter tau interactions. Among the compounds with reduced activity in the absence of DTT were the anthraquinones, benzofurans, porphyrins, pyrimidotriazines and sulphonated dyes, which raises questions about the ultimate suitability of these molecules for use in vivo.
The quinoxaline compounds did not depend on DTT for inhibition of tau fibril formation, and a bioinformatic analysis of the screening library revealed that only 2 of ~200 compounds containing a quinoxaline core structure were active in the tau assay. Both of these molecules contained a 2,3-di(furan-2yl) moiety, which might be crucial for activity. More recently, >290,000 compounds were screened at 6 concentrations, with tau fibrillization monitored using fluorescence polarization and thioflavine T fluorescence
. A total of 285 compounds showed complete dose-dependent inhibition of tau assembly, and a unique set of aminothienopyridazine inhibitors was identified that had drug-like physical and chemical attributes 115 . In summary, several distinct classes of small-molecule compounds have been identified that prevent tau fibrillization (FIG. 5) , and some of these have also been shown to disaggregate preformed fibrils or block tau aggregate formation in cells. Many of the existing tau assembly inhibitors have chemical or biological properties that will probably make them unsuitable for use in vivo, and at least some may act through the generation of reactive species or by covalent modifications that increase the potential for off-target effects. Moreover, it is possible that some of the described tau fibrillization inhibitors may form colloidal structures that have been shown to result in nonspecific inhibition of amyloid polymerization 116 . Nonetheless, continued efforts in this area are likely to yield compounds that will be suitable for analysis in mouse models of tauopathy, which will be crucial in determining the potential therapeutic merit of inhibiting tau fibril formation. In particular, it will be important to show that tau assembly inhibitors can have the desired effect of reducing tau accumulations at doses that are safe. Many of the described compounds seem to require nearly equimolar concentrations relative to tau to block fibril formation in vitro, which suggests that high concentrations might be required in the brain to achieve efficacy. However, it has been estimated that >99% of tau is bound to microtubules 117 , and so the free tau concentrations might be <20 nM in neurons, based on an estimate of 2 μM total tau 118 . Under these circumstances, achieving equimolar drug concentrations should be achievable with reasonable doses.
Another factor to consider in the evaluation of tau assembly inhibitors is that there has been little characterization of the tau species that accumulate in the presence of these compounds. Preferred compounds are likely to be those that prevent the initial stages of tau-tau interaction, so that they lead to an increase of tau monomers and not uncharacterized intermediate multimeric structures, which could have biological activity 119 . An understanding of the tau species that are formed in the presence of assembly inhibitors will therefore be important in interpreting results from studies conducted in animal models of tauopathy.
Enhancing intracellular tau degradation
There are two key pathways by which cells can degrade misfolded cytosolic proteins. The first is the ubiquitinproteasome system (UPS), in which proteins are modified with ubiquitin tags and subsequently degraded by the proteasome complex 120 . This requires the threading of the targeted protein into a narrow opening formed by the proteasome, thereby excluding oligomers and larger aggregates from catabolism by this route. Larger multimeric protein structures are therefore primarily degraded through macroautophagy, which requires encapsulation by an autophagosome and subsequent fusion with a hydrolase-containing lysosome 121 . There is evidence that both of these systems may be affected in the Alzheimer's disease brain [122] [123] [124] [125] [126] and, although normal tau has not been shown to use these systems, there are reports which suggest that hyperphosphorylated and misfolded tau can undergo degradation through both of these pathways. Upregulation of one or both of these catabolic systems may therefore lead to a reduction of pathological tau in Alzheimer's disease and other tauopathies. 
Lysosomotropic agent
A molecule that enters the lysosome and alters its function, often by increasing the pH of this normally acidic organelle.
The involvement of the UPS in the degradation of phosphorylated tau has been shown through the use of inhibitors of heat shock protein 90 (HSP90). HSP90 is a molecular chaperone that combines with other proteins to form a complex that assists in the refolding of denatured proteins in an ATP-dependent process. If the ATPase function of HSP90 is inhibited with molecules such as geldanamycin, the composition of the refolding complexes can change such that proteins which were once stabilized by HSP90 are targeted for degradation by the proteasome (discussed in more detail in ReFs 127, 128) . Inhibitors of HSP90 have been extensively studied as possible cancer therapies as it seems that many oncogenic proteins are stabilized through interactions with HSP90. In cells overexpressing mutated human tau, several HSP90 inhibitors reduced the levels of tau phosphorylated at the proline-directed kinase sites Ser202-Thr205 and Ser396-Ser404 (ReF. 129) . Moreover, tau with an altered conformation that is recognized by a specific antibody was decreased in cells treated with HSP90 inhibitors. Two studies have shown that treating transgenic mice that express human tau with BBBpermeant HSP90 inhibitors (FIG. 4) -ec102 for 7 days, or PU24Fcl for 1 month -reduced the amount of hyperphosphorylated tau in the brain 127, 130 . Interestingly, ec102 was found to displace biotinlabelled geldanamycin from HSP90 complexes in cortical homogenates from human Alzheimer's disease brains at 1000-fold lower concentration than in homogenates derived from control cortex or nonaffected Alzheimer's disease cerebellum 127 . This is in keeping with the discovery that the HSP90 inhibitor 17-allylaminogeldanamycin has a 100-fold higher binding affinity for HSP90 derived from tumour cells than for HSP90 from normal cells 131 . These data suggest that there is a preferential binding of HSP90 inhibitors to complexes that are associated with misfolded proteins, and imply that HSP90 inhibitors can be used clinically at doses that will leave other HSP90 -client protein interactions intact.
Although HSP90 inhibitors seem to hold promise for reducing phosphorylated and misfolded monomeric tau through the UPS, it is unlikely that this strategy would affect larger tau oligomers and fibrils. However, the autophagic clearance system has been implicated in the removal of aggregate-prone proteins, including those involved in neurodegenerative disease 121, 132 . Macroautophagy can be induced with the drug rapamycin, and it has been shown that treatment of flies that express wild-type or mutated tau with this compound results in a reduction of insoluble tau and associated toxicity 133 . Recently, it was found that clearance of tau was slowed in human tau-expressing neuroblastoma cells that were treated with the lysosomotropic agents NH 4 cl or chloroquine 134 . Furthermore, addition of the autophagy inhibitor 3-methyladenine led to enhanced tau accumulation and aggregation 134 . There is therefore growing evidence that aggregated tau can be degraded by autophagy and that an upregulation of the autophagylysosomal system with drugs such as rapamycin might be a potential strategy for the treatment of tauopathies. Unfortunately, rapamycin affects the mammalian Box 2 | High-throughput screens used to identify inhibitors of tau fibril formation Full-length tau (also known as MAPT) or certain tau fragments can be induced to form fibrils that closely resemble those isolated from diseased brains. Tau monomers have a highly disorganized structure and will not spontaneously assemble into fibrils unless an anionic cofactor, such as heparin or arachidonic acid, is included in the incubation mixture. When one of these anionic species is added to a tau preparation and incubated at 37°C, a time-dependent increase in fibril content is observed that can be detected using dyes such as thioflavine S or thioflavine T (ThT), which emit a characteristic fluorescence signal upon binding to cross-β-fibril structures (see the figure) 137 . An alternative detection method involves adding a small amount of fluorophore-labelled tau to the fibril formation assay 115 . The fluorescent tau is incorporated in growing tau multimers, which slows the rotational freedom of the fluorescent probe and causes an increase in fluorescence polarization (FP) (see the figure) . Whereas ThT will only bind tau fibrils, the fluorescence polarization method allows for the detection of both non-fibrillar and fibrillar multimeric tau species. The fluorescence polarization and ThT readouts can be performed in the same reaction. This can help to distinguish compounds that inhibit the early stages of tau assembly (resulting in a diminution of both fluorescence polarization and ThT fluorescence) from those that primarily affect fibril growth (leading to diminished ThT fluorescence but a lesser decrement of fluorescence polarization). Tau fibril formation assays of this type have been miniaturized so that fibrils can be reproducibly formed in 384-well or 1536-well plates, thereby allowing large compound libraries to be screened for molecules that inhibit tau fibril formation. Nature Reviews | Drug Discovery 
Prodromal disease
The earliest phase of a developing condition or disease.
target of rapamycin (mToR) signalling network and has pleiotropic effects, including immuno suppression, that complicate its use. In this regard, inhibition of an mToR-independent target, inositol monophosphatase, with Licl has been shown to cause an upregulation of autophagy and an increased clearance of α-synuclein, which forms intracellular inclusions in Parkinson's disease 135 . As discussed above, many studies have been conducted using Licl in tauopathy models in which changes in aggregated tau levels were attributed to inhibition of GSK3. It is possible that Licl might have also induced autophagy in these models, and it will be important to further study whether inositol monophosphatase inhibition affects tau aggregates in cell-based models and tau-transgenic mice.
Conclusions
There is clearly growing interest in tau-focused drug discovery for Alzheimer's disease and other tauopathies, and this has resulted in important advances in this area. A number of small molecules have been identified that target tau-mediated neuropathology and neurodegeneration (FIG. 6) . These include compounds that inhibit tau multimerization, decrease tau phosphorylation through inhibition of kinases or O-GlcNAcase, enhance tau degradation or compensate for tau LoF through stabilization of microtubules. However, only a limited number of tau kinase inhibitors, HSP90 inhibitors and microtubule-stabilizing agents have undergone proof-ofprinciple testing in established transgenic mouse models of tauopathy. Moreover, the only tau-directed drugs that have progressed to human clinical testing are methylene blue, Licl and NAP. It is hoped that many additional compounds that target tau pathology will soon be examined for efficacy in vivo, as such studies are important in further validating the use of tau-based therapeutic approaches.
As tau-directed therapies move towards clinical testing in Alzheimer's disease and other tauopathies, they will face many of the difficulties that are presently being encountered in trials of Aβ-targeted drugs. Foremost among these is the challenge of demonstrating clinical efficacy in a population that is likely to have substantial existing neurodegeneration. efforts are underway to improve early Alzheimer's disease diagnosis and to identify those with prodromal disease, as such patients should be more responsive to disease-modifying treatments. However, conducting clinical trials at an early disease stage presents other difficulties, including the possibility of having to follow patient response for longer time periods. This challenge might be mitigated by the identification of informative efficacy biomarkers for Alzheimer's disease and related tauopathies. Although there is considerable uncertainty about the relative roles of Aβ and tau in Alzheimer's disease, the greater correlation of memory impairment with NFTs than with Aβ-containing plaques suggests that tau pathology is temporally closer to the neurodegenerative events that result in dementia than the Aβ aggregates. If this proves to be the case, clinical efficacy in Alzheimer's disease may be more readily demonstrated with tau-directed drugs than with those targeting Aβ. It is therefore important to further pursue tau-focused drug discovery programmes so that candidates are identified for future clinical assessment. A number of approaches are being pursued to reduce the consequences of pathological tau (also known as MAPT) in Alzheimer's disease and related tauopathies. It is thought that tau sequestration in neurofibrillary tangles (NFTs) results in a loss of normal tau stabilization of microtubules and/or the formation of toxic tau multimeric structures. Small-molecule microtubule-stabilizing agents might compensate for a reduction in tau interaction with microtubules. Tau hyperphosphorylation reduces its binding to microtubules and enhances its fibrillization, and inhibitors of tau kinases might therefore both improve microtubule function and reduce the formation of pathological tau multimers. Because tau O-glycosylation and phosphorylation seem to be reciprocally regulated, inhibition of β-N-acetylglucosaminidase (O-GlcNAcase) might be another approach to decreasing tau hyperphosphorylation. Another potential strategy to increase the amount of soluble tau that is available for microtubule binding and decrease potentially toxic aggregates is to inhibit the assembly of tau into larger multimeric structures or dissolve existing aggregates (using tau assembly inhibitors). Finally, it may be possible to increase the degradation of misfolded and aggregated tau. Heat shock protein 90 (HSP90) inhibitors might increase proteasomemediated clearance of misfolded and/or hyperphosphorylated tau monomers, whereas enhancers of autophagy have the potential to increase the removal of tau aggregates. See FIG. 5 for examples of compounds targeting these processes.
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